» Articles » PMID: 22956816

Antiphospholipase A2 Receptor Antibody Titer and Subclass in Idiopathic Membranous Nephropathy

Overview
Specialty Nephrology
Date 2012 Sep 8
PMID 22956816
Citations 151
Authors
Affiliations
Soon will be listed here.
Abstract

The phospholipase A(2) receptor (PLA(2)R) is the major target antigen in idiopathic membranous nephropathy. The technique for measuring antibodies against PLA(2)R and the relationship between antibody titer and clinical characteristics are not well established. Here, we measured anti-PLA(2)R (aPLA(2)R) antibody titer and subclass in a well defined cohort of 117 Caucasian patients with idiopathic membranous nephropathy and nephrotic-range proteinuria using both indirect immunofluorescence testing (IIFT) and ELISA. We assessed agreement between tests and correlated antibody titer with clinical baseline parameters and outcome. In this cohort, aPLA(2)R antibodies were positive in 74% and 72% of patients using IIFT and ELISA, respectively. Concordance between both tests was excellent (94% agreement, κ=0.85). Among 82 aPLA(2)R-positive patients, antibody titer significantly correlated with baseline proteinuria (P=0.02). Spontaneous remissions occurred significantly less frequently among patients with high antibody titers (38% versus 4% in the lowest and highest tertiles, respectively; P<0.01). IgG4 was the dominant subclass in the majority of patients. Titers of IgG4, but not IgG1 or IgG3, significantly correlated with the occurrence of spontaneous remission (P=0.03). In summary, these data show high agreement between IIFT and ELISA assessments of aPLA(2)R antibody titer and highlight the pathogenetic role of these antibodies, especially the IgG4 subclass, given the observed relationships between aPLA(2)R titer, baseline proteinuria, and outcome.

Citing Articles

Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy.

Rovin B, Ronco P, Wetzels J, Adler S, Ayoub I, Zaoui P Kidney Int Rep. 2024; 9(9):2635-2647.

PMID: 39291206 PMC: 11403052. DOI: 10.1016/j.ekir.2024.06.018.


Therapeutic targets in membranous nephropathy: plasma cells and complement.

Tomas N Clin Kidney J. 2024; 17(9):sfae243.

PMID: 39239361 PMC: 11375337. DOI: 10.1093/ckj/sfae243.


A review of progress on complement and primary membranous nephropathy.

Yu S, Sun J Medicine (Baltimore). 2024; 103(29):e38990.

PMID: 39029058 PMC: 11398747. DOI: 10.1097/MD.0000000000038990.


Expression and Clinical Significance of Non B Cell-Derived Immunoglobulins in the Urinary System and Male Reproductive System.

Deng Z, Wang Y, Qin C, Sheng Z, Xu T, Qiu X Adv Exp Med Biol. 2024; 1445:101-117.

PMID: 38967753 DOI: 10.1007/978-981-97-0511-5_8.


Combined evaluation of glomerular phospholipase A2 receptor and immunoglobulin G subclass in membranous nephropathy.

Ueki K, Tsuchimoto A, Matsukuma Y, Ataka E, Okamoto H, Tanaka S Clin Kidney J. 2024; 17(6):sfae104.

PMID: 38854426 PMC: 11161704. DOI: 10.1093/ckj/sfae104.


References
1.
Beck Jr L, Bonegio R, Lambeau G, Beck D, Powell D, Cummins T . M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009; 361(1):11-21. PMC: 2762083. DOI: 10.1056/NEJMoa0810457. View

2.
Qin W, Beck Jr L, Zeng C, Chen Z, Li S, Zuo K . Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011; 22(6):1137-43. PMC: 3103733. DOI: 10.1681/ASN.2010090967. View

3.
Buis B, Wever P, Koomen G, van Acker B, Groothoff J, Krediet R . Clearance ratios of amylase isoenzymes and IgG subclasses: do they reflect glomerular charge selectivity?. Nephron. 1997; 75(4):444-50. DOI: 10.1159/000189583. View

4.
van den Brand J, Hofstra J, Wetzels J . Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2011; 6(12):2846-53. PMC: 3255374. DOI: 10.2215/CJN.04020411. View

5.
Cattran D . Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol. 2005; 16(5):1188-94. DOI: 10.1681/ASN.2005010028. View